Ph3 Study of Enfortumab Vedotin + Pembro in Muscle Invasive Bladder Cancer
Phase III Clinical Trial
C5701009 - A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY